Background: Methadone maintenance therapy remains the most common form of substitution therapy for opioid use disorder in Canada. Effectiveness of methadone maintenance therapy has been established, but recently newer treatment delivery models have emerged. Differences across these treatment models have not been examined.
Purpose: This descriptive qualitative study used semi-structured interviews to assess client experiences in three methadone maintenance therapy treatment delivery models: (a) comprehensive programs, (b) low-threshold/high-tolerance programs, and (c) fee-for-service programs.
Methods: A total of 32 participants were recruited from methadone maintenance therapy clinics in an Atlantic Canadian city and grouped into three models of care ( = 9, = 11, = 12). Content analysis was performed on interview data to assess the frequency of relevant themes in the data.
Results: Participants from all groups stressed the importance of supportive staff and having access to some form of counselling. However, low-threshold/high-tolerance and fee-for-service clients voiced a need for more formal counselling and programming at their clinics. Methadone was reported as the most helpful aspect of the methadone maintenance therapy programs; however, participants also expressed negative views about the substance.
Conclusions: These findings have important implications for the development and implementation of methadone maintenance therapy, specifically pertaining to further integration of addiction and mental health services.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/0844562120924516 | DOI Listing |
BMC Psychiatry
January 2025
School of Mental Health, Bengbu Medical University, Bengbu, Anhui, 233030, China.
Background: Although impaired cognitive control is common during the acute detoxification phase of substance use disorders (SUD) and is considered a major cause of relapse, it remains unclear after prolonged methadone maintenance treatment (MMT). The aim of the present study was to elucidate cognitive control in individuals with heroin use disorder (HUD) after prolonged MMT and its association with previous relapse.
Methods: A total of 63 HUD subjects (41 subjects with previous relapse and 22 non-relapse subjects, mean MMT duration: 12.
J Public Health (Oxf)
January 2025
Faculty of Public Health, University of Medicine and Pharmacy at Ho Chi Minh City. 217 Hong Bang, District 5, Ho Chi Minh City 70000, Viet Nam.
Background: Methadone maintenance treatment (MMT) is effective for treating opioid dependence. However, nonadherence can increase the risk of withdrawal syndrome, relapse, and overdose.
Methods: A community-based randomized controlled trial was conducted on 450 opioid-dependent patients undergoing MMT at three clinics in Ho Chi Minh City, Vietnam.
JAMA Netw Open
January 2025
San Francisco Department of Public Health, San Francisco, California.
Importance: The rise of high-potency opioids such as fentanyl makes buprenorphine initiation challenging due to the risks of precipitated withdrawal, prompting the exploration of strategies, such as low-dose initiation (LDI) of buprenorphine. However, no comparative studies on LDI outcomes exist.
Objective: To evaluate outpatient outcomes associated with 2 LDI protocols of buprenorphine among individuals with opioid use disorder (OUD) using fentanyl.
Pain Manag
January 2025
Department of Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Introduction: The QTc prolongation effect of methadone has been extensively studied at higher doses commonly used in opioid dependence maintenance therapy, but evidence remains limited regarding its impact at the lower doses typically prescribed for cancer pain. This study aims to evaluate the effect of oral methadone on QTc intervals in cancer pain patients.
Methods: A retrospective analysis was performed on adult patients initiated on oral methadone therapy for cancer.
Hum Vaccin Immunother
December 2025
School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.
ClinicalTrials.gov (NCT03962816).https://clinicaltrials.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!